

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

**DELAY IN DESPATCH OF CIRCULAR IN RELATION TO
(1) VERY SUBSTANTIAL ACQUISITION IN RELATION TO
ACQUISITION OF TRANSFERRED PRODUCTS,
IN-LICENSING OF LICENSED PRODUCTS AND PROPOSED ISSUE OF
CONSIDERATION SHARES UNDER SPECIFIC MANDATE
AND
(2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO
THE PURCHASE ARRANGEMENT, ROYALTY PAYMENTS AND
MILESTONE PAYMENTS**

Reference is made to the announcement (the “**Announcement**”) of Ocumention Therapeutics (the “**Company**”) dated August 12, 2024. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

As stated in the Announcement, a circular (the “**Circular**”) containing, among other things, (a) details of (i) the Acquisition, the In-Licensing and the Share Issue; (ii) the valuation report in respect of the value of the rights under the acquisition of the Transferred Products and the in-licensing of the Licensed Products; and (iii) the continuing connected contractions in relation to the purchase arrangement, royalty payments and sales milestone payments; (b) a letter of advice from the Independent Board Committee to the independent Shareholders; and (c) a letter of advice from Gram Capital to the Independent Board Committee and the independent Shareholders, and other information required to be disclosed under the Listing Rules, together with a notice of the EGM, was expected to be despatched to the Shareholders on or before September 2, 2024.

As additional time is required to prepare and finalize certain information to be included in the Circular, it is expected that the despatch date of the Circular will be postponed to a date falling on or before September 16, 2024.

By order of the Board
Ocumention Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, September 2, 2024

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.